Investors

Financial press releases

Financial press releases

16 September 2021, Sophia Antipolis, France

Median Technologies has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world, and selected to implement their clinical trial imaging strategy on some key oncology indications

This is the result of the renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company. The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years. This partnership will contribute to sustain Median’s future bookings and revenues growth.

Read more
6 September 2021, Sophia Antipolis, France

Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort

Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx[1] to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort. Results show cutting-edge performance of 95.2% sensitivity and 95.7% specificity for lung nodule characterization that could significantly impact lung cancer screening programs adoption. The large-scale study is based on a cohort of 1,696 patients with a total of 15,608 lung nodules. Further results on a fully automated end-to-end lung cancer screening CADe/CADx including nodule detection and characterizationre expected in Q4, 2021.

Read more

Filter financial press releases by year